Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Epidemiol ; 34(8): 393-401, 2024 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-38191178

RESUMEN

The Tsuruoka Metabolomics Cohort Study (TMCS) is an ongoing population-based cohort study being conducted in the rural area of Yamagata Prefecture, Japan. This study aimed to enhance the precision prevention of multi-factorial, complex diseases, including non-communicable and aging-associated diseases, by improving risk stratification and prediction measures. At baseline, 11,002 participants aged 35-74 years were recruited in Tsuruoka City, Yamagata Prefecture, Japan, between 2012 and 2015, with an ongoing follow-up survey. Participants underwent various measurements, examinations, tests, and questionnaires on their health, lifestyle, and social factors. This study uses an integrative approach with deep molecular profiling to identify potential biomarkers linked to phenotypes that underpin disease pathophysiology and provide better mechanistic insights into social health determinants. The TMCS incorporates multi-omics data, including genetic and metabolomic analyses of 10,933 participants, and comprehensive data collection ranging from physical, psychological, behavioral, and social to biological data. The metabolome is used as a phenotypic probe because it is sensitive to changes in physiological and external conditions. The TMCS focuses on collecting outcomes for cardiovascular disease, cancer incidence and mortality, disability and functional decline due to aging and disease sequelae, and the variation in health status within the body represented by omics analysis that lies between exposure and disease. It contains several sub-studies on aging, heated tobacco products, and women's health. This study is notable for its robust design, high participation rate (89%), and long-term repeated surveys. Moreover, it contributes to precision prevention in Japan and East Asia as a well-established multi-omics platform.


Asunto(s)
Metabolómica , Humanos , Persona de Mediana Edad , Adulto , Japón/epidemiología , Femenino , Masculino , Anciano , Estudios de Cohortes , Biomarcadores
2.
J Stroke Cerebrovasc Dis ; 32(7): 107152, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-37137198

RESUMEN

OBJECTIVES: Spinal dural arteriovenous fistula (sDAVF) is a rare and often underdiagnosed spinal disease. Early diagnosis is required because the deficits are reversible and delays in treatment cause permanent morbidity. Although the abnormal vascular flow void is a critical radiographic feature of sDAVF, they are not always present. A characteristic enhancement pattern of sDAVF has been recently reported as the "missing-piece" sign which can lead to the early and correct diagnosis. METHODS: We presented imaging findings, treatment decisions, and the outcome of a rare case of sDAVF, in which the "missing-piece" sign appeared atypical. RESULTS: A 60-year-old woman developed numbness and weakness in her extremities. Spinal MRI revealed longitudinal hyperintensity in the T2-weighted image, extending from the thoracic level to medulla oblongata. At first, myelopathy with inflammation or tumor was suspected because of the lack of flow voids and vascular abnormalities in CT-angiography and MR-DSA. However, we administered intravenous methylprednisolone and her symptom got worse with the appearance of the "missing-piece" sign. Then, we successfully diagnosed sDAVF by angiography. The "missing-piece" sign was considered to derive from inconsistency of the intrinsic venous system of spinal cord, with the abrupt segments without enhancement. The same etiology was considered in our case. CONCLUSIONS: Detecting the "missing-piece" sign can lead to the correct diagnosis of sDAVF, even if the sign appeared atypical.


Asunto(s)
Malformaciones Vasculares del Sistema Nervioso Central , Enfermedades de la Médula Espinal , Humanos , Femenino , Persona de Mediana Edad , Enfermedades de la Médula Espinal/etiología , Médula Espinal/diagnóstico por imagen , Médula Espinal/irrigación sanguínea , Imagen por Resonancia Magnética/métodos , Angiografía/efectos adversos , Malformaciones Vasculares del Sistema Nervioso Central/complicaciones , Malformaciones Vasculares del Sistema Nervioso Central/diagnóstico por imagen , Malformaciones Vasculares del Sistema Nervioso Central/terapia
3.
Mar Drugs ; 19(5)2021 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-34068940

RESUMEN

Carotenoids are used commercially for dietary supplements, cosmetics, and pharmaceuticals because of their antioxidant activity. In this study, colored microorganisms were isolated from deep sea sediment that had been collected from Suruga Bay, Shizuoka, Japan. One strain was found to be a pure yellow carotenoid producer, and the strain was identified as Sphingomonas sp. (Proteobacteria) by 16S rRNA gene sequence analysis; members of this genus are commonly isolated from air, the human body, and marine environments. The carotenoid was identified as nostoxanthin ((2,3,2',3')-ß,ß-carotene-2,3,2',3'-tetrol) by mass spectrometry (MS), MS/MS, and ultraviolet-visible absorption spectroscopy (UV-Vis). Nostoxanthin is a poly-hydroxy yellow carotenoid isolated from some photosynthetic bacteria, including some species of Cyanobacteria. The strain Sphingomonas sp. SG73 produced highly pure nostoxanthin of approximately 97% (area%) of the total carotenoid production, and the strain was halophilic and tolerant to 1.5-fold higher salt concentration as compared with seawater. When grown in 1.8% artificial sea salt, nostoxanthin production increased by 2.5-fold as compared with production without artificial sea salt. These results indicate that Sphingomonas sp. SG73 is an efficient producer of nostoxanthin, and the strain is ideal for carotenoid production using marine water because of its compatibility with sea salt.


Asunto(s)
Sedimentos Geológicos/microbiología , Sphingomonas/aislamiento & purificación , Sphingomonas/metabolismo , Xantófilas/aislamiento & purificación , Xantófilas/metabolismo , Japón , Filogenia , ARN Bacteriano/genética , ARN Ribosómico 16S/genética , Sales (Química)/farmacología , Agua de Mar , Sphingomonas/genética , Espectrometría de Masas en Tándem , Xantófilas/análisis , Xantófilas/química
4.
J Stroke Cerebrovasc Dis ; 30(10): 106051, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34419835

RESUMEN

OBJECTIVES: An association has been reported between delays in the onset-to-door (O2D) time for mechanical thrombectomy (MT) and outbreaks of coronavirus disease 2019 (COVID-19). However, the association between other MT time courses or functional outcomes and COVID-19 outbreaks remains unclear. We compared the time courses of stroke pathways or functional outcomes in 2020 (the COVID-19 era) with those in 2019 (the pre-COVID-19 era) in Tokyo, Japan. MATERIALS AND METHODS: This retrospective observational study used data from the Tokyo-tama-REgistry of Acute endovascular Thrombectomy (TREAT), a multicenter registry of MT for acute large vessel occlusion in the Tokyo Metropolitan Area. Patients who had undergone acute MT from January 2019 to December 2020 were included. Patients were classified by the year they had undergone MT (2019 or 2020). RESULTS: In total, 477 patients were analyzed. O2D time was significantly longer in 2020 (146.0 min) than in 2019 (105.0 min; p = 0.034). No significant difference in door-to-puncture time (D2P) time or modified Rankin Scale (mRS) score 0-2 at 90 days was seen between 2019 and 2020. In the subgroup analysis, O2D time was significantly longer in the first half of 2020 compared with 2019. Multivariable logistic regression analysis revealed that the year 2020 was a independent predictor of longer O2D time, but not for mRS score 0-2 at 90 days. CONCLUSIONS: Although O2D time was significantly longer in the COVID-19 compared with the pre-COVID-19 era, D2P may not be significantly delayed and functional outcomes may not be different, despite the COVID-19 pandemic.


Asunto(s)
COVID-19 , Pautas de la Práctica en Medicina/tendencias , Accidente Cerebrovascular/terapia , Trombectomía/tendencias , Tiempo de Tratamiento/tendencias , Asignación de Recursos para la Atención de Salud/tendencias , Necesidades y Demandas de Servicios de Salud/tendencias , Humanos , Sistema de Registros , Estudios Retrospectivos , Accidente Cerebrovascular/diagnóstico , Factores de Tiempo , Tokio , Resultado del Tratamiento
5.
J Stroke Cerebrovasc Dis ; 27(12): 3605-3612, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30220629

RESUMEN

BACKGROUND: The efficacy and safety of antiplatelet drugs in the treatment of moyamoya disease remain unclear. This study reports results of a nationwide survey conducted in 2016 on the trends of antiplatelet therapy for moyamoya disease in Japan. METHODS: Data were obtained through questionnaires related to treatment policies regarding antiplatelet drugs from each specialized stroke management department of 765 hospitals in Japan. Data were also compared between experienced facilities (defined as facilities managing more than 10 cases per year) and those less experienced (not more than 10 cases per year) to determine experts' opinion. RESULTS: Of the 389 departments in 375 hospitals that responded, 330 departments provided medical care for moyamoya disease. Regarding ischemic stroke, numerous departments considered the use of antiplatelet drugs "in principle" (218 departments). After surgery for ischemic moyamoya disease, the use of antiplatelet drugs for a certain period of time was the most popular opinion (74 departments). Regarding asymptomatic moyamoya disease, majority departments reported no use of APDs "in principle" (256 departments). The experienced facilities reported "no use of antiplatelet drugs" more frequently than those less experienced for treating asymptomatic moyamoya disease. In moyamoya disease, aspirin was the most commonly used antiplatelet drugs followed by cilostazol and clopidogrel. CONCLUSIONS: This survey revealed details of treatment policies, and the selection of antiplatelet drugs widely varied across facilities. Further prospective studies are necessary to improve the current unclear situation regarding the use of antiplatelet drugs for the management of moyamoya disease.


Asunto(s)
Enfermedad de Moyamoya/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/cirugía , Manejo de la Enfermedad , Humanos , Japón , Enfermedad de Moyamoya/cirugía
6.
J Stroke Cerebrovasc Dis ; 24(11): e315-7, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26350694

RESUMEN

BACKGROUND: Various sensory impairments have been reported in patients with lateral medullary syndrome, also known as Wallenberg syndrome. The typical sensory impairments experienced by patients with this condition are ipsilateral facial and contralateral trunk and limb thermal hypesthesia and hypoalgesia. Tactile (light touch) sensation is not generally diminished. Here we report the case of a 35-year-old man with lateral medullary infarction who had atypical sensory impairment. METHODS: We examined the results from the neurological examination of the patient as well as findings from computed tomography of the head and magnetic resonance imaging. RESULTS: Magnetic resonance imaging showed left lateral medullary infarction caused by left posterior inferior cerebellar artery dissection. Neurological examination revealed both tactile and thermal/pain hypesthesia on the left side of the patient's face, and thermal/pain hypesthesia on his right upper and lower limbs. CONCLUSION: There are two types of tactile sensation: epicritic and protopathic. Facial tactile sensation is usually thought to be associated with epicritic tactile sensation, which travels through principal sensory nuclei of the trigeminal nerve. The protopathic pathway travels down through the spinal tract via the trigeminal nerve and is not considered a primary pathway. However, in this case the protopathic tactile sensation pathway might be involved, and it caused facial tactile hypesthesia. Because most of previous case reports and literature reviews focused only on thermal/pain hypesthesia, we believe that this case provides critical information on the brainstem neuroanatomy, especially for the protopathic tactile sensation pathway in patients with stroke.


Asunto(s)
Cara/inervación , Lateralidad Funcional/fisiología , Hipoestesia/etiología , Síndrome Medular Lateral/complicaciones , Adulto , Imagen de Difusión por Resonancia Magnética , Humanos , Masculino
7.
Keio J Med ; 73(3): 27-30, 2024 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-38987205

RESUMEN

Some patients develop ischemic stroke despite taking direct oral anticoagulants because of the presence of other risk factors such as coagulopathies. A 65-year-old male patient with non-valvular atrial fibrillation (NVAF) taking rivaroxaban was diagnosed as having embolic stroke and antithrombin-III (AT-III) deficiency. Echocardiography revealed a thrombus in the left atrial appendage (LAA). He was prescribed warfarin, and after resolution of the thrombus, we successfully performed percutaneous LAA closure (LAAC), with no subsequent recurrence or device-related thrombosis. Warfarin and LAAC may be feasible for NVAF patients with AT-III deficiency.


Asunto(s)
Anticoagulantes , Deficiencia de Antitrombina III , Apéndice Atrial , Fibrilación Atrial , Warfarina , Humanos , Fibrilación Atrial/cirugía , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Masculino , Anciano , Apéndice Atrial/cirugía , Apéndice Atrial/diagnóstico por imagen , Warfarina/uso terapéutico , Warfarina/administración & dosificación , Anticoagulantes/uso terapéutico , Anticoagulantes/administración & dosificación , Deficiencia de Antitrombina III/complicaciones , Deficiencia de Antitrombina III/tratamiento farmacológico , Trombosis/prevención & control , Resultado del Tratamiento , Rivaroxabán/uso terapéutico , Rivaroxabán/administración & dosificación , Ecocardiografía , Cierre del Apéndice Auricular Izquierdo
8.
J Oleo Sci ; 73(10): 1319-1328, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39313395

RESUMEN

The beneficial effects of a formulated supplement of plasmalogen and elastin on the memory function in healthy elderly subjects were investigated by a randomized, double-blind, placebo-controlled, parallel-group analysis. Plasmalogen has been shown to exert beneficial effects on cognitive function in animal models and human clinical trials, while elastin improves vascular elasticity and increases blood flow. The levels of plasmalogen and elastin decreases with aging. The supplement containing Ascidiacea (Halocynthia-roretzi)-derived plasmalogen (0.5 mg) and Tuna-derived elastin (100 mg) was administered to elderly Japanese subjects once a day for 16 weeks. The Japanese version of Rivermead Behavioral Memory Test (RBMT) was used as a primary evaluation item for the assessment of memory. Data from a protocolmatched population (per protocol set) (n=123) were analyzed. A comparison of mean difference between the baseline and evaluation points in cognition function in RBMT showed significantly higher scores for the categories of "first name" and "face recognition" in the test group than in the placebo group. In the stratified analysis of subjects ≧ 75 years, the test group scored significantly higher than the placebo group for the categories of "belonging", "face recognition and picture recognition". The stratified analysis of female subjects showed a significantly higher scores for categories of "first and second names" and "belonging" of RBMT in the test group. Also, the score of "physical functioning" was significantly higher in the test group. These results indicate that formulated supplement of plasmalogen and elastin may be beneficial for improving memory dysfunction in healthy elderly subjects.


Asunto(s)
Suplementos Dietéticos , Elastina , Memoria , Plasmalógenos , Atún , Humanos , Método Doble Ciego , Anciano , Femenino , Masculino , Memoria/efectos de los fármacos , Animales , Plasmalógenos/administración & dosificación , Plasmalógenos/farmacología , Cognición/efectos de los fármacos , Anciano de 80 o más Años , Pueblos del Este de Asia
9.
Clin Neurol Neurosurg ; 231: 107859, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37390571

RESUMEN

We treated a 37-year-old Japanese woman with moyamoya disease who developed cerebral infarction in the early period after pregnancy and had undergone infertility treatment. After being adequately informed, including regarding the risk of stroke in the perinatal period and the option to prioritize the treatment of moyamoya disease even if the pregnancy was interrupted, the patient decided to continue the pregnancy and underwent surgical treatment after a full-term delivery by caesarean section. No new stroke was observed throughout the perinatal period or postoperative course. Since serious stroke during the perinatal period has also been reported in moyamoya disease, it is important to plan "tailored" treatment by sufficiently informing patients considering individual backgrounds and for multiple medical departments, including obstetrics, neurology, and neurosurgery departments, to carry out close outpatient follow-up in the perinatal period and carefully careful medication usage and radiological examinations.


Asunto(s)
Infarto Cerebral , Revascularización Cerebral , Enfermedad de Moyamoya , Complicaciones del Embarazo , Humanos , Femenino , Adulto , Enfermedad de Moyamoya/complicaciones , Enfermedad de Moyamoya/diagnóstico , Enfermedad de Moyamoya/cirugía , Infarto Cerebral/complicaciones , Infarto Cerebral/diagnóstico , Infarto Cerebral/cirugía , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/cirugía , Cesárea , Embarazo , Resultado del Tratamiento
10.
Case Rep Neurol Med ; 2023: 9152009, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38045988

RESUMEN

We report a patient with a symptomatic intraluminal internal carotid artery thrombus clinically revealed by cerebral infarction. In the preoperative evaluation, it was revealed that essential thrombocythemia existed in the background. Therefore, medical treatment with antithrombotic agents in conjunction with hydroxycarbamide for essential thrombocythemia was initiated, but the thrombus was not dissolved by three weeks. At this time, the patient underwent carotid endarterectomy, which removed the thrombus completely with its adjacent plaque without any perioperative stroke. The possibility of essential thrombocythemia may also be kept in mind when an increased platelet count is observed in patients with internal carotid artery thrombus. It is a reasonable option to precede medical treatment, including anticoagulant therapy, by setting the time limit for surgical intervention in such a disease state.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA